Introduction
The TCR-CD3 complex is composed of TCR (αβ or γδ) heterodimers associated with CD3 (γε dimer and δε dimer) and ζζ dimer (or ζη) (reviewed in 1). The invariant CD3 and the ζζ dimer are required for optimal surface expression of TCR and for TCR-dependent signal transduction (1, 2) . The CD3 complex contains multiples of a highly conserved motif, ITAM, an acronym for the immunoreceptor tyrosine-based activation motif (3) (4) (5) (6) . There is one ITAM in each of the γ, δ and ε chains, but three ITAM are present in the ζ chain. Each ITAM contains a pair of YxxL/I motifs separated by 10 or 11 amino acids. The tyrosine residues are rapidly phosphorylated after TCR cross-linking and the phosphorylated motifs serve as docking sites for other signaling proteins by binding through their src homology 2 (SH2) domains. Because there Received 29 April 1998, accepted 5 August 1998 is micro-heterogeneity among the sequences of individual ITAM and preferential binding of some ITAM to certain kinases of the activation cascade, it has been suggested that individual ITAM could specifically couple to the SH2 domains of individual signaling proteins to generate distinct functions (7) (8) (9) . On the other hand, the presence of multiple ITAM may simply provide a mechanism for signal amplification, with different activation thresholds required for distinct functions. It is also possible that the 'specificity model' and the 'threshold model' are not mutually exclusive, and may be differentially utilized depending on specific conditions of T cell activation. Activation-induced T cell death (AICD) occurs when the TCR molecules of recently activated peripheral T cells are cross-linked (10) (11) (12) . AICD plays a critical role in maintaining lymphocyte homeostasis and peripheral tolerance because animals that are defective in AICD develop an autoimmune lymphoproliferative syndrome (13) (14) (15) (16) . Whether AICD falls in the context of the 'specificity' model and/or the 'threshold' model remains unresolved. AICD can be induced in vitro by a two-stage T cell activation protocol: an initial 3 day activation period that primes the T cells, followed by re-stimulation for 16 h to induce cell death. The requirement for re-activation of the recently activated T cells suggests that a high threshold of activation must be reached in order to trigger the AICD program. Other studies have implicated a specific signaling pathway for AICD through the ζ chain of the TCR-CD3 complex (17) . It has been shown that AICD was severely impaired in T cells lacking the ITAM of ζ chain. Conversely, AICD can be induced in hybridoma T cells over-expressing a fusion protein bearing the ITAM of the ζ chain and the extracellular domain of CD8 (17) . Under identical conditions, only weak AICD was observed with the ITAM of the ε chain (17) . Also, recent studies using altered-ligand peptides (ALP) to stimulate the various functions of cloned T cells have raised the possibility that AICD is induced via a specific signaling pathway following TCR engagement (18) .
To understand the role of the TCR-CD3 complex and the role of individual ITAM in T cell activation and AICD, we have studied AICD of T cells from CD3ζ -/-mice and T cells from CD3ζ -/-mice transgenically expressing a truncated ζ lacking the cytoplasmic domain (amino acid 67-150) (CD3ζ -/-:Tg ζ∆67-150 ) (19) . The peripheral T cells of the former strain express extremely low or undetectable levels of TCR (20) . The latter strain expresses normal levels of TCR but without the ITAM associated with the ζ chain (19) . By using a powerful polyclonal activation protocol, we were able to induce proliferation and TCR expression in the T cells of CD3ζ -/-mice. Since the T cells prepared from CD3ζ -/-, CD3ζ -/-:Tg ζ∆67-150 and control mice differ either with regard to the TCR level or with regard to the ITAM associated with the TCR-CD3 complex, it is possible to address the issue of 'threshold' versus 'specificity' model in this system of AICD. Our study demonstrates that the signal strength required for the induction of AICD is regulated by the extent of TCR-CD3 cross-linking and that ITAM not associated with the ζ chain in the TCR-CD3 complex can transduce a signal sufficient for the induction of AICD. These findings support the signal threshold model for TCR-induced AICD.
Methods

Mouse strains
Breeding pairs of homozygous perforin knockout mice (Po) were obtained from Dr W. R. Clark (UCLA, Los Angeles, CA) (21). They were maintained at the Laboratories of Animal Science Center, Boston University Medical Center, Boston, MA. The generation and characterization of CD3ζ -/-mice has been described (20) . The CD3ζ -/-:Tg ζ∆67-150 mice were obtained from Dr P. Love (NIH, Bethesda, MD). Both the CD3ζ -/-and the CD3ζ -/-:Tg ζ∆67-150 mice were maintained at the Animal facility, Beth-Israel Hospital, Harvard Medical School, Boston, MA. The C57BL/6 and SCID mice were purchased from the Jackson Laboratories (Bar Harbor, ME). Both male and female mice, 2-6 months old, were used.
Reagents
Concanavalin A (Con A) and ionomycin were purchased from Calbiochem (San Diego, CA). phorbol 12-myristate 13-acetate (PMA) and Protein A-beads were obtained from Sigma (St Louis, MO). Ficoll-Hypaque was obtained from Pharmacia (Piscataway, NJ). Sodium chromate (Na 2 51 CrO 4 ) and [ 3 H]methyl-thymidine were obtained from New England Nuclear (Boston, MA). Fluorochrome-conjugated mAb anti-CD16/ 32(2.4G2), anti-CD3ε (145-2C11), anti-CD4 (RM4-5) and anti-CD8α (53-6.7) were purchased from PharMingen (San Diego, CA). Recombinant IL-1 (rIL-1) was kindly provided by Dr M. E. Dorf, Harvard Medical school, Boston, MA. rIL-2 was obtained from Dr M. Gately (Hoffman La-Roche, Nutley, NJ). Hybridoma 145-2C11 was obtained from Dr J. Bluestone (University of Chicago, IL). Anti-CD3ε mAb were purified by Protein A column-affinity chromatograph from ascites generated in SCID mice. The Fas-Ig-producing cell line was kindly provided by Dr. P. Leder (Harvard Medical School, Boston, MA). The Fas-Ig fusion protein was obtained from SCID sera and purified by a Protein A column as described (22) T cell proliferation Single-cell suspensions were prepared from lymph nodes. T cell proliferation was carried out in 96-well plates in triplicates. Lymph node cells (4ϫ10 5 ) were incubated with various T cell activation agents in 0.2 ml in a 37°C, 10% CO 2 incubator. Two days later, [ 3 H]thymidine (1 µCi/20 µl) was added and radioactivity incorporated into DNA was determined using a PHD harvester. Agents used for activation included Con A (2.5 µg/ml), PMA (10 ng/ml) ϩ ionomycin (0.5 µM), 145-2C11 anti-CD3ε mAb (3 µg/ml) with or without rIL-2 (75 U/ml). In addition, 1000 units of rIL-1 was also added to each well.
AICD
Preparation of T cells for AICD was carried out as described above with the exception that lymph node cells were activated in 24-well plates using 2.5-4ϫ10 6 cells/well. In some experiments, viable cells were purified at 3 days after activation by Ficoll-Hypaque gradient centrifugation and then directly restimulated. For most experiments, activated T cells (0.5ϫ10 6 ) were maintained in rIL-2 (75 U/ml) for an additional 3 days, and then the rIL-2-treated cells were purified and used for the AICD assays. Cells were mildly labeled with Na 2 51 CrO 4 for 35 min and washed 2 times with culture medium. Labeled cells (7.5ϫ10 4 to 10 5 ) were added to wells that had been coated with various amounts of ant-CD3ε mAb. Cells cultured in wells not coated with anti-CD3ε were used as controls for background release. All cultures were supplemented with rIL-2 (75 U/ml). Supernatants were collected 16 h later and counted with a γ-counter. The results were expressed as percent AICD using the formula: 100ϫ[(experimental c.p.m. -background c.p.m.)/(total release -background c.p.m.)]. Background release was between 15 and 40% of the total radioactivity. No correlation between background release and a specific pattern of AICD was observed. Total release was generated by the addition of 0.2% Triton X-100 to culture.
Flow cytometric analysis
The method used for cell surface phenotypic analysis has been described (23) . Lymphocytes, either freshly isolated 
Results
Induction of proliferation of lymph node cells from CD3ζ -/-mice
Since AICD requires prior T cell activation, it is important to determine the degree of T cell activation before using the activated T cells for AICD analysis. Therefore, T cell mitogenic responses were determined for lymph node cells from CD3ζ -/-, CD3ζ -/-:Tg ζ∆67-150 and normal control mice. Lymph node cells were stimulated with polyclonal T cell mitogens, Con A, anti-CD3ε or PMA ϩ ionomycin, as described in Methods (Table 1) . T cells from Po mice exhibited a strong proliferative response when activated by Con A or anti-CD3ε mAb for 3 days. The response to PMA ϩ ionomycin was moderate. Similar results were obtained from C57BL/6 T cells (data not shown). The response of CD3ζ -/-T cells to Con A, anti-CD3ε or PMA ϩ ionomycin was extremely low or undetectable. The defect in the proliferative response was corrected in T cells from the CD3ζ -/-:Tg ζ∆67-150 mice, indicating that surface expression of the TCR-CD3 complex is required for the various conditions of polyclonal mitogenic stimulation. Lymph node cells from each mouse strain responded to rIL-2 although a slightly lower response was observed for T cells from CD3ζ -/-mice. Interestingly, PMA ϩ ionomycin but not Con A or anti-CD3ε cooperated with rIL-2 to induce a strong proliferation of the lymph node cells of CD3ζ -/-mice. Thus, this method of activation was used to generate activated cells from CD3ζ -/-mice for the analysis of AICD.
Expression of CD3 by activated T cells from CD3ζ -/-mice As PMA ϩ ionomycin, but not anti-CD3ε or Con A induces proliferation of lymph node cells of CD3ζ -/-mice in the presence of rIL-2, it was important to determine whether most or only a fraction of the activated cells are CD3-expressing T cells. T cell analyses were conducted with the 3 day activated cells that had been maintained in rIL-2 for an additional 3 days (Fig. 1) . Two-color fluorescent staining using PE-anti-CD3ε and FITC-conjugated anti-CD4 and anti-CD8 showed that the great majority of cells from C57BL/6 (95%), CD3ζ -/-:Tg ζ∆67-150 (89%) and CD3ζ -/-(92%) mice were T cells (Fig.  1A) . In contrast to the comparable expression of CD4/CD8, the expression of CD3ε ϩ varied significantly. While 95% and 83% of CD3ε ϩ T cells were observed for normal and CD3ζ -/-:Tg ζ∆67-150 mice respectively, the percentage of CD3ε ϩ T cells in the CD3ζ -/-cell preparation was only~18%. The question arises as to what kind of CD3 complex is generated in the T cells of CD3ζ -/-mice. It has been demonstrated that in the absence of the ζ chain, the γ chain of the FcγR (and FcεRI) can substitute for the ζ chain and form functional CD3 complexes (20, 24, 25) . Two-color fluorescent staining using PE-anti-CD3ε and FITC-anti-FcγR (anti-CD16/32) showed that almost all of the CD3ε ϩ cells were confined to the FcR ϩ population (Fig. 1B) . These data suggest that in the absence of the ζ chain, the CD3 complexes are formed with the γ chain of the FcγR. Such T cells have been demonstrated in the intestinal intraepithelial lymphocytes in the CD3ζ -/-mice and in T cells of CD3ζ -/-mice transgenically expressing the γ chain of the FcεRI (24, 25) .
ACID can be detected in the activated T cells of CD3ζ -/-mice The availability of activated T cells from normal, CD3ζ -/-and CD3ζ -/-:Tg ζ∆67-150 mice offers a good opportunity to study the role of surface TCR levels and individual ITAM in AICD. Therefore, T cells were activated under the same condition as described in the cell surface study described above and then analyzed for AICD. The results were shown in Fig. 2 . T cells generated from control mice exhibited strong AICD.
Optimal AICD was induced in wells coated with 0.15-1 µg anti-CD3ε mAb. The threshold of anti-CD3 required for AICD was low, i.e. significant AICD was still observed in wells coated with 0.05 µg anti-CD3ε mAb (Fig. 2a) . In contrast, both the maximal level of AICD and the ability of coated anti- Tg ζ∆67-150 mice. Lymph node T cells were activated by PMA ϩ ionomycin ϩ rIL-2 for 3 days. Viable cells were purified and cultured in rIL-2 for an additional 3 days before being assayed for AICD as described in Methods. Background release was 15-35% and no apparent correlation was observed between background release and AICD. Each curve represents an individual sample. The difference of AICD between normal and CD3ζ -/-:Tg ζ∆67-150 is insignificant (P ϭ 0.26, at α value of 0.05, two-tail t-test). The difference between normal and CD3ζ -/-mice is significant (P ϭ 0.002, at α value of 0.05, twotail t-test).
CD3ε mAb to induce AICD were dramatically reduced in CD3ζ -/-T cells. This is consistent with the low level of CD3 and the low percentage of CD3ε ϩ T cells in this population (see Fig. 1 ). Nevertheless, there was a moderate expression of AICD, but the induction of AICD occurred only in wells coated with the highest dose of anti-CD3ε used (Fig. 2b) . By comparing with normal T cells, a 10-fold excess of anti-CD3ε mAb was needed to compensate for the CD3 signaling deficiency in CD3ζ -/-T cells. Indeed, staining of CD3ε revealed~10-fold difference between the two preparations ( Fig. 1 ). The data demonstrate that the effect of the ζ chain on the AICD of CD3ζ -/-T cells is primarily due to the inability of CD3ζ -/-T cells to assemble sufficient levels of the CD3 complex for surface expression rather than the lack of ITAM associated with the ζ chain. a Lymph node T cells were activated by PMA ϩ ionomycin ϩ rIL-2 for 3 days and then cultured in rIL-2 for an additional 3 days. Cells were purified by Ficoll-Hypaque gradient centrifugation, 51 Cr-labeled, and used. T cells from Po mice were used as control. Each line represents an individual sample.
b AICD assays were carried out in duplicates in wells coated with anti-CD3ε mAb. For control and CD3ζ -/-:Tg ζ∆67-150 mice, 96-well plates coated with 0.3 µg were used. For CD3ζ -/-mice, wells coated with 1 µg were used.
c The concentration of inhibitors was 10 µg/ml in all cases.
That the low level of surface CD3 was responsible for the low AICD was further supported by the study of CD3ζ -/-:Tg ζ∆67-150 mice. A remarkable reversal of the T cell responsiveness in wells coated with low amounts of anti-CD3ε was observed, i.e. AICD was induced in wells coated with 0.15 µg/ml anti-CD3ε mAb (Fig. 2c) . The data demonstrate that T cell sensitivity to anti-CD3ε depends more on the surface level of TCR-CD3 complex and less on the ITAM of the ζ chain. The optimal level of AICD (18-40%) was slightly lower than T cells from control mice, although statistically insignificant. Activated T cells from CD3ζ -/-:Tg ζ∆67-150 mice exhibit normal AICD It has been reported in one study that activated T cells from CD3ζ -/-:Tg ζ∆67-150 mice are unable to mount a significant AICD response upon re-activation by plate-bound anti-CD3ε (17) . This result suggests a critical role of the ITAM of the ζ chain in the delivery of signals required for AICD. However, the data presented in Fig. 2(c) do not agree with the result of the previous study. The CD3ζ -/-:Tg ζ∆67-150 mouse strain does not show a severe autoimmune phenotype associated Fig. 3 . AICD of T cells from control (circle) and CD3ζ -/-:Tg ζ∆67-150 (triangle) mice. Lymph node T cells were activated by Con A ϩ rIL-1 for 3 days. Viable cells were purified and assayed for AICD as described in Methods. Background release was 25-40% and no apparent correlation was observed between background release and AICD. Each curve represents an individual sample.
Fas-Ig inhibits AICD of T cells from
with the AICD defect. Moreover, their normal mitogenic response and IL-2 production reflect respectively normal TCR-CD3-and IL-2-mediated signals, which are required for AICD (1, 17, 26, 27) . To confirm our observation that normal AICD can be induced in T cells from CD3ζ -/-:Tg ζ∆67-150 mice (Fig. 2c) , AICD was induced in lymph node T cells that had been activated with Con A ϩ rIL-1 for 3 days. This is the standard activation protocol for inducing AICD of peripheral T cells (10, 11, 28) . It is significant that exogenous rIL-2 was not used in this protocol and that an activation protocol different from PMA ϩ ionomycin ϩ rIL-2 was used to verify our observation. The results shown in Fig. 3 demonstrated that AICD could be induced in T cells from both normal control and the CD3ζ -/-:Tg ζ∆67-150 mice. Moreover, both the extent of AICD and the amount of anti-CD3ε required for maximal induction of AICD were comparable between the two strains of mice. The data indicate that the AICD program is not defective in CD3ζ -/-:Tg ζ∆67-150 mice and that ITAM of the ζ chain are not essential for the induction of AICD.
Discussion
As a critical mechanism regulating peripheral tolerance and preventing activated lymphocytes from unlimited expansion, AICD occurs after recently activated T cells are re-activated by TCR cross-linking. The present study is based on this concept and uses this system to address the role of individual components of the TCR-CD3 complex and their associated ITAM on AICD. AICD is critically dependent on TCR-CD3-mediated signals. A threshold model would predict that there is a lower limit of TCR-CD3 expression necessary to transduce an AICD signal. The present study took the advantage of the fact that activated CD3ζ -/-T cells express ഛ10% the normal level of CD3ε. Even though their CD3 complexes lack ζ chains, AICD can still be induced in CD3ζ -/-T cells. Our quantitative study indicates that there is at least a 10-fold difference between normal and CD3ζ -/-T cells in the amount of anti-CD3ε required for the induction of AICD. The data demonstrate that the surface level of TCR-CD3 is a critical factor regulating AICD and that the ζ chain is not essential for the expression of AICD.
It is interesting that we have succeeded in generating CD3ε ϩ T cells from the lymph nodes of CD3ζ -/-mice. Previous studies have shown that the γ chain, shared by the FcγR and FcεRI, can substitute for the ζ chain to form functional TCR-CD3 complexes (24, 25) . The activated T cells from CD3ζ -/-mice expressed high levels of FcγR and almost all of the CD3ε ϩ cells were included in the FcγR ϩ population. The data obtained by flow cytometric analysis indicate that the CD3ε level was~10% of normal control. This level is significantly lower than the TCR levels observed with intraepithelial lymphocytes of the CD3ζ -/-mice (23, 24) . The low level of CD3ε correlated with the weak induction of AICD and the requirement for large amounts of plate-bound anti-CD3ε to activate the AICD program.
To what extent the AICD is regulated by the levels of surface TCR-CD3 complex and the associated ITAM is addressed by studying the AICD of the CD3ζ -/-:Tg ζ∆67-150 T cells. These mice express normal levels of TCR-CD3 complex but lack the ITAM associated with the ζ chains. The normal surface TCR levels correlate with a normal threshold for AICD induction, as determined by the minimal amount of anti-CD3ε required for the process. In agreement with the study using CD3ζ -/-mice, the data also indicate that the ITAM of the ζ chain are not essential for the expression of normal level of AICD. It should be emphasized that ITAM of the ζ chain are sufficient for the induction of AICD as demonstrated in hybridoma T cells transfected with constructs containing the extracellular domain of CD8 and the cytoplasmic domain of the ζ chain (17) . Taken together, these studies demonstrate that the signal required for AICD can be transduced through either the ITAM of γ, δ and ε or the ITAM of the ζ chain.
Studies from several groups have shown that T cells from CD3ζ -/-:Tg ζ∆67-150 mice exhibit normal mitogenic responses and produce normal levels of IL-2 (17, 26) . We also showed that the T cell proliferative response of the CD3ζ -/-:Tg ζ∆67-150 mice to a variety of T cell activation conditions was similar to normal mice. Moreover, we showed that activated T cells of CD3ζ -/-:Tg ζ∆67-150 mice are capable of undergoing AICD. Our result differs from a previous study which showed that there was a significant reduction in the AICD of CD3ζ -/-:Tg ζ∆67-150 T cells (17) . The disparity may be due to differences in the activation conditions. In the previous study, T cells were derived by a 2 day stimulation with PMA ϩ ionomycin (without rIL-2) followed by a 2 day culture in rIL-2. The two activation conditions we used for the CD3ζ -/-:Tg ζ∆67-150 T cells were Con A and PMA ϩ ionomycin ϩ rIL-2. The T cells activated by the latter protocol were further cultured in rIL-2 for 3 days. Our activation conditions generated highly reproducible AICD as shown by the induction of AICD in the large number of experiments conducted in this study. Interestingly, it was stated in the Discussion in the previous study that there could be significant AICD induced in these T cells following prolonged stimulation (17) . The presence of a normal AICD mechanism is consistent with the fact that no autoimmune lymphoproliferative syndrome has been observed for the CD3ζ -/-:Tg ζ∆67-150 strain. Our standard activation conditions aided by IL-2 (either produced by the responder cells or provided exogenously) quickly induce the activated T cells to proliferate rapidly and become sensitive to AICD.
The data obtained of CD3ζ -/-:Tg ζ∆67-150 T cells demonstrate that T cells expressing normal levels of TCR-CD3 but without the ITAM of ζ chain can undergo AICD with a threshold of stimulation comparable to wild-type T cells. In this regard, it was shown that the ζ chain of IL-2-treated proliferating T cells was not phosphorylated under the re-activation conditions that induced AICD (29) . Moreover, an APL could induce AICD without phosphorylating the ζ chain (18) . These observations are consistent with our conclusion that the ITAM of the ζ chain are not required for AICD.
Our data support the hypothesis that the ITAM of the TCR-CD3 complex are redundant and compensatory. According to this hypothesis, the presence of multiple ITAM on the TCR-CD3 complex is to safeguard the various vital functions resulting from T cell activation (such as IL-2 production and AICD) when genetic defects prevent the expression of one or a few of the ITAM of the CD3 complex. The specificity model would put a host at higher risk if a single ITAM controlled a single vital immune function.
The controversy as to whether various signals mediated through the TCR-CD3 complex are regulated by a threshold of activation or by specific activation pathways is currently under extensive study. Partial signaling has been demonstrated in cloned T cells by using ALP that selectively induce AICD but not the production of certain lymphokines (18) . These ALP also induce different tyrosine phosphorylation patterns of the components of TCR-CD3 complex (9, 18, 30) . These findings are consistent with the specificity model of T cell signaling. However, the concentration of the ALP required for AICD induction was 10 3 -10 4 higher than wild-type peptide, suggesting that the low-affinity peptides could only generate weak stimulus and a high concentration was needed to overcome the threshold required for FasL gene activation. This interpretation is consistent with the threshold model. Interestingly, ALP did not always induce tyrosine phosphorylation of the ζ chain, suggesting that the ζ chain is not required for AICD (18) . The results obtained with cloned T cells using ALP are consistent with the present study using a heterogeneous population of peripheral T cells. Both studies are compatible with the threshold model, but do not exclude the specificity model suggested in some of the ALP systems. We would argue that if a specific signal is responsible for AICD, the ITAM of the ζ chain are not required for the process. We could further argue that even if a specific signaling pathway is involved, the threshold of activation provided by the specific signal must also be a critical factor for AICD as indicated by the results obtained with activated T cells of CD3ζ -/-mice.
